Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Osanetant

Targets (1)

Identification

Name

Osanetant

Accession Number

DB04872

Type

Small Molecule

Groups

Investigational

Description

Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

Structure

Similar Structures

Synonyms

Not Available

External IDs

SR 142801 / SR-142801 / SR142801

Categories

UNII

K7G81N94DT

CAS number

160492-56-8

Weight

Average: 606.625
Monoisotopic: 605.257582985

Chemical Formula

C₃₅H₄₁Cl₂N₃O₂

InChI Key

DZOJBGLFWINFBF-UMSFTDKQSA-N

InChI

InChI=1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1

IUPAC Name

N-(1-{3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-N-methylacetamide

SMILES

CN(C(C)=O)C1(CCN(CCC[[email protected]@]2(CCCN(C2)C(=O)C2=CC=CC=C2)C2=CC(Cl)=C(Cl)C=C2)CC1)C1=CC=CC=C1

Pharmacology

Indication

Potential therapy for schizophrenia, depression and visceral pain.

Structured Indications

Not Available

Pharmacodynamics

Osanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.

Mechanism of action

The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.

Target	Actions	Organism
UNeuromedin-K receptor	Not Available	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	Osanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	Osanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Osanetant may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Osanetant.	Experimental
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Osanetant.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Aceprometazine is combined with Osanetant.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Osanetant is combined with Adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine.	Approved, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Osanetant is combined with Alaproclate.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Osanetant is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Osanetant.	Approved, Illicit
Allopregnanolone	The risk or severity of adverse effects can be increased when Osanetant is combined with Allopregnanolone.	Investigational
Almotriptan	The risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant.	Approved, Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Osanetant.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Osanetant is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant.	Approved, Illicit, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Osanetant is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Osanetant is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Osanetant is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Osanetant is combined with Amperozide.	Experimental
Amphetamine	Osanetant may decrease the stimulatory activities of Amphetamine.	Approved, Illicit
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Asenapine is combined with Osanetant.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Osanetant is combined with Azaperone.	Vet Approved
Azelastine	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Osanetant is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.	Illicit
Benperidol	The risk or severity of adverse effects can be increased when Osanetant is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Benzocaine is combined with Osanetant.	Approved
Benzphetamine	Osanetant may decrease the stimulatory activities of Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Osanetant is combined with Benzyl alcohol.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Osanetant is combined with Brexpiprazole.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Osanetant.	Approved, Illicit
Bromisoval	The risk or severity of adverse effects can be increased when Osanetant is combined with Bromisoval.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Osanetant is combined with Bromperidol.	Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Osanetant is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Osanetant.	Approved, Investigational
Buprenorphine	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Osanetant.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Osanetant is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Osanetant is combined with Butamben.	Approved
Butethal	The risk or severity of adverse effects can be increased when Butethal is combined with Osanetant.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant.	Approved, Illicit, Vet Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant.	Approved
Canertinib	The risk or severity of adverse effects can be increased when Osanetant is combined with Canertinib.	Investigational
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Osanetant is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Osanetant.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Osanetant is combined with Carisoprodol.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Osanetant is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Osanetant.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Osanetant.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Chlormezanone is combined with Osanetant.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Osanetant is combined with Chlorphenamine.	Approved
Chlorphentermine	Osanetant may decrease the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Osanetant.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Osanetant is combined with Chlorzoxazone.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Citalopram is combined with Osanetant.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Osanetant is combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Osanetant is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Osanetant is combined with Clobazam.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when Osanetant is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Osanetant is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Clonidine.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Osanetant is combined with Clopenthixol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Osanetant.	Approved, Illicit
Clothiapine	The risk or severity of adverse effects can be increased when Osanetant is combined with Clothiapine.	Experimental
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Osanetant.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Cocaine is combined with Osanetant.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Osanetant.	Approved, Illicit
Cyclizine	The risk or severity of adverse effects can be increased when Osanetant is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Osanetant is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Osanetant is combined with Dantrolene.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Osanetant.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Osanetant is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Osanetant is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Osanetant.	Approved
Detomidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Osanetant.	Approved, Vet Approved
Dextroamphetamine	Osanetant may decrease the stimulatory activities of Dextroamphetamine.	Approved, Illicit
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Osanetant.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Osanetant.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Osanetant.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Osanetant.	Approved, Illicit, Vet Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Osanetant is combined with Diethyl ether.	Experimental
Diethylpropion	Osanetant may decrease the stimulatory activities of Diethylpropion.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Osanetant is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Osanetant.	Approved, Illicit
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Osanetant.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Osanetant.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Osanetant is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Osanetant.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Osanetant.	Approved, Illicit
Dixyrazine	The risk or severity of adverse effects can be increased when Osanetant is combined with Dixyrazine.	Experimental
Doramectin	The risk or severity of adverse effects can be increased when Osanetant is combined with Doramectin.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Osanetant is combined with Doxepin.	Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Osanetant is combined with DPDPE.	Investigational
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Drotebanol is combined with Osanetant.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Ecgonine is combined with Osanetant.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Osanetant is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.	Approved, Investigational
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Osanetant is combined with Eltanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Osanetant.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Osanetant is combined with Entacapone.	Approved, Investigational
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant.	Approved
Escitalopram	The risk or severity of adverse effects can be increased when Escitalopram is combined with Osanetant.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Osanetant.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant.	Approved
Ethanol	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Osanetant.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Osanetant is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Osanetant is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Osanetant.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Osanetant is combined with Ethyl chloride.	Experimental
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Osanetant.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Osanetant.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Osanetant is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Osanetant is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Osanetant is combined with Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Osanetant.	Illicit, Vet Approved
Ezogabine	The risk or severity of adverse effects can be increased when Osanetant is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Osanetant is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Fencamfamine is combined with Osanetant.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Osanetant is combined with Fexofenadine.	Approved
Flibanserin	The risk or severity of adverse effects can be increased when Osanetant is combined with Flibanserin.	Approved
Fluanisone	The risk or severity of adverse effects can be increased when Osanetant is combined with Fluanisone.	Experimental
Fludiazepam	The risk or severity of adverse effects can be increased when Fludiazepam is combined with Osanetant.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Osanetant is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Osanetant.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Fluoxetine is combined with Osanetant.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Osanetant.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Fluspirilene is combined with Osanetant.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Osanetant is combined with Fluticasone propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Osanetant.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Osanetant is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Osanetant is combined with Fospropofol.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Osanetant.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Osanetant.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Osanetant is combined with Gabapentin Enacarbil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Osanetant.	Approved, Illicit
Gepefrine	Osanetant may decrease the stimulatory activities of Gepefrine.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Osanetant is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Glutethimide is combined with Osanetant.	Approved, Illicit
Guanfacine	The risk or severity of adverse effects can be increased when Osanetant is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Halazepam is combined with Osanetant.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.	Approved
Halothane	The risk or severity of adverse effects can be increased when Halothane is combined with Osanetant.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Osanetant.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant.	Approved
Hydrocodone	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Osanetant.	Approved, Illicit
Hydroxyamphetamine	Osanetant may decrease the stimulatory activities of Hydroxyamphetamine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Osanetant is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.	Investigational, Withdrawn
Indiplon	The risk or severity of adverse effects can be increased when Osanetant is combined with Indiplon.	Investigational
Iofetamine I-123	Osanetant may decrease the stimulatory activities of Iofetamine I-123.	Approved
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Osanetant.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Osanetant.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Osanetant is combined with Ketobemidone.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Osanetant is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Osanetant is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Osanetant.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Osanetant is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Osanetant is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Osanetant is combined with Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Osanetant.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Osanetant.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Osanetant.	Approved, Vet Approved
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant.	Approved, Investigational
Lisdexamfetamine	Osanetant may decrease the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lithium	Lithium may increase the neurotoxic activities of Osanetant.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Osanetant is combined with Lofentanil.	Illicit
Loprazolam	The risk or severity of adverse effects can be increased when Osanetant is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Osanetant is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Osanetant.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Osanetant is combined with Lormetazepam.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Osanetant.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Osanetant is combined with Maprotiline.	Approved
Mebicar	The risk or severity of adverse effects can be increased when Osanetant is combined with Mebicar.	Experimental
Meclizine	The risk or severity of adverse effects can be increased when Osanetant is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Osanetant is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Medetomidine.	Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Melatonin is combined with Osanetant.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Osanetant is combined with Melperone.	Approved
Mephedrone	Osanetant may decrease the stimulatory activities of Mephedrone.	Investigational
Mephentermine	Osanetant may decrease the stimulatory activities of Mephentermine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Osanetant is combined with Meptazinol.	Experimental
Mequitazine	Osanetant may increase the arrhythmogenic activities of Mequitazine.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Osanetant.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Osanetant.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Osanetant.	Approved, Illicit
Methamphetamine	Osanetant may decrease the stimulatory activities of Methamphetamine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Methaqualone is combined with Osanetant.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant.	Approved
Methotrimeprazine	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Osanetant.	Approved, Vet Approved
Methoxyphenamine	Osanetant may decrease the stimulatory activities of Methoxyphenamine.	Experimental
Methsuximide	The risk or severity of adverse effects can be increased when Osanetant is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Methylecgonine is combined with Osanetant.	Experimental
Methylphenidate	The risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Osanetant.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant.	Approved, Investigational
Metyrosine	Osanetant may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.	Approved, Illicit
Midomafetamine	Osanetant may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.	Experimental, Illicit
Milnacipran	The risk or severity of adverse effects can be increased when Milnacipran is combined with Osanetant.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Investigational
Mirtazapine	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
MMDA	Osanetant may decrease the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant.	Approved
Molindone	The risk or severity of adverse effects can be increased when Molindone is combined with Osanetant.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Osanetant.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Osanetant.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Osanetant.	Approved, Investigational
Nefazodone	The risk or severity of adverse effects can be increased when Nefazodone is combined with Osanetant.	Approved, Withdrawn
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Osanetant.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Osanetant.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Osanetant is combined with Norflurane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Osanetant is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Osanetant is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Osanetant is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Ondansetron is combined with Osanetant.	Approved
Opium	The risk or severity of adverse effects can be increased when Osanetant is combined with Opium.	Approved, Illicit
Orphenadrine	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Oxethazaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Osanetant.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Osanetant.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant.	Approved, Investigational, Vet Approved
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Osanetant.	Approved
Paraldehyde	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Paroxetine is combined with Osanetant.	Approved, Investigational
Penfluridol	The risk or severity of adverse effects can be increased when Osanetant is combined with Penfluridol.	Experimental
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.	Approved, Vet Approved
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved
Perazine	The risk or severity of adverse effects can be increased when Osanetant is combined with Perazine.	Investigational
Perospirone	The risk or severity of adverse effects can be increased when Osanetant is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Osanetant.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Osanetant.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Osanetant is combined with Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Osanetant.	Approved
Phenibut	The risk or severity of adverse effects can be increased when Osanetant is combined with Phenibut.	Experimental
Phenobarbital	The risk or severity of adverse effects can be increased when Phenobarbital is combined with Osanetant.	Approved
Phenoperidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Phenoperidine.	Experimental
Phenoxyethanol	The risk or severity of adverse effects can be increased when Osanetant is combined with Phenoxyethanol.	Approved
Phentermine	Osanetant may decrease the stimulatory activities of Phentermine.	Approved, Illicit
Phenytoin	The risk or severity of adverse effects can be increased when Osanetant is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Osanetant is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Osanetant is combined with Piritramide.	Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Osanetant is combined with Pizotifen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.	Approved
Pramipexole	Osanetant may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant.	Approved, Illicit
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Osanetant.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Prilocaine is combined with Osanetant.	Approved
Primidone	The risk or severity of adverse effects can be increased when Osanetant is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Procaine is combined with Osanetant.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant.	Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Osanetant is combined with Promethazine.	Approved
Propanidid	The risk or severity of adverse effects can be increased when Osanetant is combined with Propanidid.	Experimental
Proparacaine	The risk or severity of adverse effects can be increased when Proparacaine is combined with Osanetant.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Osanetant.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Osanetant is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Osanetant is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Osanetant is combined with PSD502.	Investigational
Pseudoephedrine	Osanetant may decrease the stimulatory activities of Pseudoephedrine.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.	Approved
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Osanetant.	Approved
Quinisocaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Osanetant is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Osanetant is combined with Ramelteon.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Osanetant.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Osanetant.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Osanetant is combined with Ritanserin.	Investigational
Ritobegron	Osanetant may decrease the stimulatory activities of Ritobegron.	Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Osanetant.	Approved
Romifidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Romifidine.	Vet Approved
Ropinirole	Osanetant may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant.	Approved
Rotigotine	Osanetant may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Osanetant.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Osanetant is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Osanetant.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Osanetant is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Osanetant is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Sertraline is combined with Osanetant.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Osanetant is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Osanetant is combined with Sulpiride.	Approved
Sultopride	The risk or severity of adverse effects can be increased when Osanetant is combined with Sultopride.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Osanetant.	Approved, Investigational
Suvorexant	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Osanetant is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Osanetant is combined with Tasimelteon.	Approved
Tedizolid Phosphate	The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Osanetant.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Osanetant.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Osanetant is combined with Tetrodotoxin.	Investigational
Thalidomide	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Osanetant.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Osanetant.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Osanetant.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Osanetant is combined with Tiapride.	Approved, Investigational
Tiletamine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tilidine.	Experimental
Tizanidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Tizanidine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Osanetant is combined with Tolcapone.	Approved, Withdrawn
Topiramate	The risk or severity of adverse effects can be increased when Osanetant is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Osanetant.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Osanetant.	Approved
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Osanetant is combined with Tricaine methanesulfonate.	Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Osanetant is combined with Trichloroethylene.	Experimental
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.	Approved
Trifluperidol	The risk or severity of adverse effects can be increased when Osanetant is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Osanetant.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Osanetant is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Triprolidine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Osanetant.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Osanetant.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Osanetant is combined with Veralipride.	Experimental
Vigabatrin	The risk or severity of adverse effects can be increased when Osanetant is combined with Vigabatrin.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Vilazodone is combined with Osanetant.	Approved
Vinyl ether	The risk or severity of adverse effects can be increased when Osanetant is combined with Vinyl ether.	Experimental
Vortioxetine	The risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine.	Approved
Xenon	The risk or severity of adverse effects can be increased when Osanetant is combined with Xenon.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Osanetant is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Osanetant is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Osanetant.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Osanetant is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant.	Approved, Investigational
Zolpidem	Osanetant may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Osanetant is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Osanetant.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Osanetant is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I: Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry. 2005 Jan;38(1):24-9. [PubMed:15706463]
Kamali F: Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs. 2001 Jul;2(7):950-6. [PubMed:11757797]

External Links

PubChem Compound: 219077
PubChem Substance: 175426879
ChemSpider: 189901
BindingDB: 50291261
ChEMBL: CHEMBL346178

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Clinical Trials: Not Available

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.000154 mg/mL	ALOGPS
logP	6.47	ALOGPS
logP	6.27	ChemAxon
logS	-6.6	ALOGPS
pKa (Strongest Basic)	9.3	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	43.86 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	172.73 m³·mol^-1	ChemAxon
Polarizability	66.11 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9486
Blood Brain Barrier	+	0.9882
Caco-2 permeable	+	0.5767
P-glycoprotein substrate	Substrate	0.6866
P-glycoprotein inhibitor I	Inhibitor	0.7694
P-glycoprotein inhibitor II	Inhibitor	0.837
Renal organic cation transporter	Inhibitor	0.5525
CYP450 2C9 substrate	Non-substrate	0.8013
CYP450 2D6 substrate	Non-substrate	0.6861
CYP450 3A4 substrate	Substrate	0.7427
CYP450 1A2 substrate	Non-inhibitor	0.9532
CYP450 2C9 inhibitor	Non-inhibitor	0.9439
CYP450 2D6 inhibitor	Inhibitor	0.5109
CYP450 2C19 inhibitor	Non-inhibitor	0.8248
CYP450 3A4 inhibitor	Non-inhibitor	0.703
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7353
Ames test	Non AMES toxic	0.7977
Carcinogenicity	Non-carcinogens	0.8292
Biodegradation	Not ready biodegradable	0.994
Rat acute toxicity	2.8030 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9523
hERG inhibition (predictor II)	Inhibitor	0.8584

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as 1-benzoylpiperidines. These are compounds containing a piperidine ring substituted at the 1-position with a benzoyl group.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Benzoyl derivatives
Direct Parent: 1-benzoylpiperidines
Alternative Parents: N-benzoylpiperidines / Phenylpiperidines / Phenylbutylamines / Benzamides / Dichlorobenzenes / Aralkylamines / Aryl chlorides / Tertiary carboxylic acid amides / Acetamides / Trialkylamines
show 7 more
Substituents: N-benzoylpiperidine / 1-benzoylpiperidine / Phenylpiperidine / Phenylbutylamine / N-acyl-piperidine / Benzamide / Benzoic acid or derivatives / 1,2-dichlorobenzene / Aralkylamine / Chlorobenzene
show 25 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: Not Available

Targets

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	0.21	N/A	N/A
IC 50 (nM)	0.8	N/A	N/A
IC 50 (nM)	320	N/A	N/A	8691422
Kd (nM)	0.2	N/A	N/A	19817444 / 22574973
Kd (nM)	0.22	N/A	N/A	19817444
Kd (nM)	18.62	N/A	N/A	19817444 / 22574973
Ki (nM)	0.5	N/A	N/A	19817444
Ki (nM)	0.6	N/A	N/A	22574973
Ki (nM)	1.2	N/A	N/A	8691422 / 10090788
Ki (nM)	1.9	N/A	N/A	21376585

Details1. Neuromedin-K receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Tachykinin receptor activity
Specific Function: This is a receptor for the tachykinin neuropeptide neuromedin-K (neurokinin B). It is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order...
Gene Name: TACR3
Uniprot ID: P29371
Uniprot Name: Neuromedin-K receptor
Molecular Weight: 52201.35 Da

References

Tian G, Wilkins D, Scott CW: Neurokinin-3 receptor-specific antagonists talnetant and osanetant show distinct mode of action in cellular Ca2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol. 2007 Mar;71(3):902-11. Epub 2006 Dec 15. [PubMed:17172464]

Drug created on October 20, 2007 04:46 / Updated on October 02, 2017 05:39

Osanetant

Identification

Structure for DB04872 (Osanetant)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References